Liminatus Pharma (LIMN) Receivables - Other (2024 - 2025)

Liminatus Pharma (LIMN) posted Receivables - Other of $126275.0 for Q3 2025, little changed sequentially from $126275.0 in Q2 2025.

Liminatus Pharma (LIMN) Receivables - Other (2024 - 2025) Analysis & Trends

Liminatus Pharma has reported Receivables - Other for 2 years, with the latest figure at $126275.0 in Q3 2025.

Quarterly Receivables - Other changed N/A year-over-year to $126275.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $126275.0 (changed N/A YoY) and the FY2025 annual result came in at $3.4 million, up 2613.92% from the prior year.
Receivables - Other was little changed at $126275.0 in Q3 2025 per LIMN's latest filing, from $126275.0 in the prior quarter.
Over five years, Receivables - Other peaked at $126275.0 in Q4 2024 and troughed at $126275.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	140.00 Bn	132.14 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.31 Bn	78.32 Bn	3.93 Bn
3	Argenx Se	65.24 Bn	60.06 Bn	1.37 Bn
4	Moderna	62.41 Bn	57.27 Bn	52.00 Mn
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.18 Bn	27.88 Bn	992.69 Mn
7	BioNTech SE	28.93 Bn	10.54 Bn	668.28 Mn
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn
9	Royalty Pharma	27.28 Bn	26.44 Bn	-
10	Liminatus Pharma	251.67 Mn	251.67 Mn	-

Download Data